AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05407506 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: THYROID AI
Description: thyroid artificial intelligence diagnosis system and fine needle puncture in the diagnosis of benign and malignant thyroid nodules
Study NCT05057052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab plus regorafenib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
Study NCT05057052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib will be initiated on day 14 after cryoablation. Regorafenib 80 mg was given orally once daily on days 1-21 of a 28-day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study NCT05057052 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: US/CT-guided Percutaneous Cryoablation
Description: Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
Study NCT04681651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normobaric Hyperoxia
Description: Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
Study NCT04681651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham Normobaric Hyperoxia
Description: For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%；
Study NCT04681651 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endovascular Thrombectomy
Description: EVT is the international guidelines for the treatment of acute ischemic stroke with lage vessel occlusion.
Study NCT04681651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Thrombectomy
Description: EVT is the international guidelines for the treatment of acute ischemic stroke with lage vessel occlusion.
Study NCT04722328 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CSF metagenomic next generation sequencing (mNGS)
Description: TestCSF routine, biochemical, smear staining (Gram staining, acid fast staining, ink staining), culture and mNGS。
Study NCT04882319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP-5000 Topical Patch
Description: HP-5000, placebo and saline will be administered simultaneously
Study NCT04882319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP-5000 Placebo Patch
Description: HP-5000, placebo and saline will be administered simultaneously
Study NCT04882319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Patch
Description: HP-5000, placebo and saline will be administered simultaneously
Study NCT04815382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Upper Limb Orthosis
Description: The dynamic upper limb orthosis extends from subdeltoid level to 10 mm distal to the metacarpal-phalangeal joints. The orthosis will be tailored to include 20 degrees of wrist extension and to abduct the thumb. They made from nylon and lycra.~The orthosis will be used throughout the day, being removed when the patient lies down.~The orthosis will be used during 3 months
Study NCT05134194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine
Description: Camrelizumab in combination with capecitabine or eribulin or gemcitabine or vinorelbine
Study NCT05134194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine/eribulin/gemcitabine/vinorelbine
Description: Capecitabine or eribulin or gemcitabine or vinorelbine
Study NCT05122221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine + Cyclophosphamide
Description: Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 500mg/m²/day×3 days
Study NCT05122221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 20,000,000 IU/time infused within 15 minutes approximately every 8 hours (according to the subject's tolerance, the interval between medications can be extended to 24 hours) for a maximum usage time up to 14 days.
Study NCT05122221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRTE7A2-01 TCR-T Cell
Description: On day 0, the TCR-T cells will be administered one time, each bag of cell intravenously within 20 minutes.
Study NCT04652544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D3)
Description: Vi-De 3® Monthly Dose from Dr. Wild \& Co. AG (Muttenz, Switzerland) is a commercially available vitamin D3 supplement.
Study NCT04652544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo will be produced, consisting of the same ethanol solution as Vi-De 3® Monthly Dose, but without cholecalciferol.
Study NCT04652544 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be produced, consisting of the same ethanol solution as Vi-De 3® Monthly Dose, but without cholecalciferol.
Study NCT05656716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: The nutritional intervention will be based on a nutritional education program adapted for patients with breast cancer in active treatment. The nutritional intervention program will be based on the practical guidelines for nutrition in the oncology patient. The main objectives of the nutritional intervention will focus on preventing malnutrition, maintaining an adequate nutritional status and dietary adaptation to secondary symptomatology. To this end, an adequate energy and protein intake will be ensured and the consumption of plant-based foods will be promoted to ensure an adequate intake of vitamins, minerals and antioxidants
Study NCT05656716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Description: Weekly physical exercise guidelines will be given following the published Canadian clinical guideline recommendations combining moderate and vigorous aerobic activity. Walking will be performed 3 days a week for 30 minutes at a modified Borg scale intensity of 4-5/10, and 2 days a week for 15 minutes at a modified Borg scale intensity of 7-8/10. There will also be 5 minutes of warm-up and 5 minutes of recovery, in moderate activity at 3/10, and in vigorous activity at 4/10. In addition, 3 days per week (not coinciding with vigorous aerobic activity) of strength training at a modified Borg scale intensity of 7/10 will be included. Two sets of 8-10 repetitions will be performed, adaptable to that intensity according to the progression of the subjec
Study NCT04993820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The goal for week one will be to increase moderate-to-vigorous PA (MVPA) by 90 weekly/mins, and by 120 weekly/mins on week two. This amount of time will provide the participant with an adaptation period. The goal for weeks 3-12 will be to increase MVPA by at least 150 weekly/mins. The prescribed aerobic activities can be performed either: 1) outdoors (e.g., walking or cycling), 2) at home (e.g., in-place jogging, dancing, aerobics), or 3) with available exercise equipment if the participant already has this access. Participants will perform a series of 6 to 8 muscle strengthening (MS) exercises for the major muscle groups using elastic bands and their own bodyweight 3 times per week. All MS activities will be depicted in instructional videos available through the app. Participants will be asked to perform 2 sets of 8 to 12 repetitions (reps) per exercise during weeks 1-3, 3 sets of 8 to 12 reps per exercise during weeks 3-7, and 4 sets of 8 to 12 reps per exercise during weeks 8-12.
Study NCT04993820 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education control
Description: Participants in the education CON group will be asked to perform their usual activities and to not engage in additional PA during the intervention. Participants will receive weekly brochures and reading materials including topics related to living with HIV, healthy eating, stress management, and current Federal PA guidelines for Americans. The brochures and reading materials will be available through the BluejayEngage health web-based platform app.
Study NCT05134675 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Homemade beer
Description: The data of patients who consume and do not consume homemade beer will be cross-sectionally evaluated and compared.
Study NCT04710524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID for 13 weeks
Study NCT04710524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FM101 150 mg BID
Description: FM101 (150 mg) BID for 13 weeks
Study NCT04710524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FM101 300 mg BID
Description: FM101 (300 mg) BID for 13 weeks
Study NCT05593926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myota Metabolic Regulator
Description: The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.
Study NCT05263128 — intervention group
Intervention type: OTHER
Intervention: Investigation of the validity of the Hand-20 Questionnaire in individuals with carpal tunnel syndrome
Description: To investigate the validity and reliability of the Hand-20 questionnaire used in individuals with upper extremity disease by comparing it with the Boston carpal tunnel syndrome questionnaire in individuals with carpal tunnel syndrome in Turkey
Study NCT05585086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peppermint Oil Inhalation
Description: Peppermint oil will be given by diluting 1/10 in wheat oil so that it does not cause skin irritation. Application; by inhalation method, 2 cc lavender essential oil + 100 cc water (2%) will be in the form of two drops for 20 minutes. Since the effectiveness of essential oils decreases over time and the desired dose cannot be applied at the same time; Peppermint oil will be applied to the individual for a total of 5 times every 30 minutes.
Study NCT04838886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based Pilates Exercise
Description: The group that will receive telerehabilitation-based pilates training via telerehabilitation
Study NCT05261568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROGRESSIVE RELAXATION EXERCISE
Description: Progressive relaxation exercise will be done for 6 weeks by watching the animation video in the mobile application program.
Study NCT06273020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Cerebrolysin would be prepared according to manufacturer's instructions: 30 mL of cerebrolysin in 100 ml of saline solution every 24 hours to a minimum of 10 days and a maximum of 14 days
Study NCT06273020 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cerebrolysin
Description: Cerebrolysin would be prepared according to manufacturer's instructions: 30 mL of cerebrolysin in 100 ml of saline solution every 24 hours to a minimum of 10 days and a maximum of 14 days
Study NCT06273020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain-MRI with contrast after 10-14 days of cerebrolysin
Description: Blood-brain barrier (BBB) disruption will be measured using dynamic susceptibility contrast (DSC) magnetic resonance imaging. DSC MRI is collected during the injection of a gadolinium bolus and the majority of the change in recorded signal in this T2-weighted sequence is due to intravascular contrast. However, in the setting of gadolinium leakage through the BBB into the brain parenchyma, the recorded signal is altered by a T1 effect. An arrival time correction is performed to account for regional difference in blood flow after which the signal is separated into an intravascular and an extravascular component using a comparison with unaffected tissue.The extravascular component is captured with the metric K2 which reflects the fraction of the recorded signal that is due to gadolinium leakage and is a measure of BBB disruption.
Study NCT06273020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain-MRI with contrast after 10-14 days of cerebrolysin
Description: Blood-brain barrier (BBB) disruption will be measured using dynamic susceptibility contrast (DSC) magnetic resonance imaging. DSC MRI is collected during the injection of a gadolinium bolus and the majority of the change in recorded signal in this T2-weighted sequence is due to intravascular contrast. However, in the setting of gadolinium leakage through the BBB into the brain parenchyma, the recorded signal is altered by a T1 effect. An arrival time correction is performed to account for regional difference in blood flow after which the signal is separated into an intravascular and an extravascular component using a comparison with unaffected tissue.The extravascular component is captured with the metric K2 which reflects the fraction of the recorded signal that is due to gadolinium leakage and is a measure of BBB disruption.
Study NCT06273020 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brain-MRI with contrast after 10-14 days of cerebrolysin
Description: Blood-brain barrier (BBB) disruption will be measured using dynamic susceptibility contrast (DSC) magnetic resonance imaging. DSC MRI is collected during the injection of a gadolinium bolus and the majority of the change in recorded signal in this T2-weighted sequence is due to intravascular contrast. However, in the setting of gadolinium leakage through the BBB into the brain parenchyma, the recorded signal is altered by a T1 effect. An arrival time correction is performed to account for regional difference in blood flow after which the signal is separated into an intravascular and an extravascular component using a comparison with unaffected tissue.The extravascular component is captured with the metric K2 which reflects the fraction of the recorded signal that is due to gadolinium leakage and is a measure of BBB disruption.
Study NCT05648708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combine Adductor Canal & Sciatic Nerve Block
Description: The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia
Study NCT05648708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combine Femoral & Sciatic Nerve Block
Description: The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia
Study NCT05648708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and prilocaine hydrochloride
Description: The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
Study NCT05648708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and prilocaine hydrochloride
Description: The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
Study NCT06315049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy sessions to reduce anxiety
Study NCT05835219 — intervention group
Intervention type: DRUG
Intervention: REBYOTA™
Description: REBYOTA™ is administered in the rectum
Study NCT05297448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD
Description: Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
Study NCT05297448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Twice Daily
Study NCT05400707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of vital signs
Description: heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
Study NCT05400707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of patient mobility at presentation
Description: Patients are asked how they assess their own mobility: - Stable walking without aids or limited mobility with aids (walking aid, wheelchair, lying down).
Study NCT05400707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of level of consciousness by AVPUC scale
Description: Assessment of level of consciousness by AVPUC scale (alert, new confusion, verbal, pain, unresponsive, new confusion)
Study NCT05400707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of symptoms patients presenting when admitted to ED
Description: Questionnaire with a predefined list of 37 symptoms
Study NCT05400707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of what matters most in patients of 65 years and older
Description: Patients over the age of 65 are asked the following: generally asked: what matters most to you at the moment? and why is that important for you?.
Study NCT05400707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Decision-making in senior physicians
Description: Questionnaire consisting of 10 questions about the decision-making processes in the emergency department and the factors that form the basis of their decisions regarding the diagnosis, treatment, and disposition of the patient.
Study NCT05400707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pain Numeric Rating Scale (NRS)
Description: The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of his/her pain ('0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. pain as bad as you can imagine))
Study NCT05400707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Frailty Scale (CFS)
Description: The CFS is a commonly used score to assess frailty. It was developed within the Canadian Study of Health and Aging and consists of a 9-level ordinal scale ranging from very fit (score 1) to living with very severe frailty (score 8), and score 9 reserved for those who are terminally ill.
Study NCT05950256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N95 mask and surgical mask
Description: Twenty participants were randomly assigned to the N95 mask group (n=10 ) and the Surgical mask group (n=10 ). The N95 mask group and the Surgical mask group were used in two stages alternately. When the first round of the test was completed and after a 24-hour washing out period, the participants of the Surgical mask group and the N95 respirator group were exchanged for the second round of the test.
Study NCT05950256 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N95 mask and surgical mask
Description: Twenty participants were randomly assigned to the N95 mask group (n=10 ) and the Surgical mask group (n=10 ). The N95 mask group and the Surgical mask group were used in two stages alternately. When the first round of the test was completed and after a 24-hour washing out period, the participants of the Surgical mask group and the N95 respirator group were exchanged for the second round of the test.
Study NCT06338163 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Polihexanide-based bundle
Description: Pre- and intra-operative decontamination will be accomplished in the treatment (experimental) arm with Polihexanide-based products
Study NCT06338163 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard bundle
Description: Pre- and intra-operative decontamination will be accomplished in the control arm with normal soap/shampoo and saline solution
Study NCT04543955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat (Low-Dose)
Description: Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 750mg per day (250mg TID) for 20 months.
Study NCT04543955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat (High-Dose)
Description: Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 1500mg per day (500mg TID) for 20 months.
Study NCT04478149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafelyYou
Description: technology to detect and prevent falls
Study NCT04478149 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: technology present but not activated
Study NCT05768841 — intervention group
Intervention type: BEHAVIORAL
Intervention: mental health issues
Description: survey on mental health issues in endurance athletes
Study NCT05454202 — intervention group
Intervention type: DEVICE
Intervention: ANI
Description: Pain measurement during care procedures in palliative care
Study NCT05502471 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Zonulin
Description: Serum zonulin level
Study NCT05502471 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Occludin
Description: Serum occludin level
Study NCT04704895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Total parenteral nutrition
Description: Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
Study NCT04704895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.